CALLICUTT JACK W (Chief Financial Officer) sold 88.7% of their position (60K shares) of GALECTIN THERAPEUTICS INC on the open market
Open‑market sale worth $233.4K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 1/6/2026ACC: 0001133416-26-000006
Officer· Chief Financial Officer
Since Jan 2019
-60K
Net shares
Net seller
$233.4K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
60K acquired · 120K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+60K
Price / share
—
Trade value
—
% of position
788.0%
1/2/2026
7.61K→67.61K
Common Stock
Direct
Shares
−13.91K
Price / share
$4.20
Trade value
$58.39K
% of position
20.6%
1/2/2026
67.61K→53.70K
Common Stock
Direct
Shares
−25.73K
Price / share
$3.90
Trade value
$100.30K
% of position
47.9%
1/5/2026
53.70K→27.97K
Common Stock
Direct
Shares
−20.35K
Price / share
$3.67
Trade value
$74.70K
% of position
72.8%
1/6/2026
27.97K→7.61K
Total
Net shares
+0.00
Net value
-$233.39K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/2/2026 | M · Option Exercise | +60K | — | — | 788.0% | 7.61K | 67.61K |
| Common Stock Direct | 1/2/2026 | S · Sale | −13.91K | $4.20 | $58.39K | 20.6% | 67.61K | 53.70K |
| Common Stock Direct | 1/5/2026 | S · Sale | −25.73K | $3.90 | $100.30K | 47.9% | 53.70K | 27.97K |
| Common Stock Direct | 1/6/2026 | S · Sale | −20.35K | $3.67 | $74.70K | 72.8% | 27.97K | 7.61K |
| Total | +0.00 | -$233.39K | ||||||
Derivative Transactions1
Restricted Stock Unit
Direct
Converts to
Common Stock
60K shares
Shares
−60K
Strike price
0
Held after
0.00
Exercisable
—
1/1/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Unit Direct | Common Stock60K shares | 1/1/2026 | M · Option Exercise | −60K | 0 | — | 0.00 |